Shire On Course For 2017 Launch Of 'Adderall Beads' For Adult ADHD
This article was originally published in Scrip
Executive Summary
Shire's positive topline data from a pediatric Phase III trial of SHP465 (triple-bead mixed amphetamine salts) addresses the US FDA requirements for a class 2 resubmission for the product's NDA, said the company. The product is slated for US launch in 2017.
You may also be interested in...
Goal Finally In Sight For Shire's 'Adderall Beads' Extension Strategy
Shire is set for a refiling of its NDA by the end of the year and a potential 2017 launch with its 'Adderall beads' for ADHD.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.